TNF-α Antagonist (WP9QY) is primarily used in research and therapeutic applications targeting inflammatory and autoimmune diseases. It works by inhibiting TNF-α, a cytokine involved in systemic inflammation, which makes it valuable in studying conditions like rheumatoid arthritis, Crohn's disease, and psoriasis. In preclinical studies, WP9QY has shown potential in reducing inflammation and tissue damage by blocking TNF-α signaling pathways. It is also utilized in experimental models to understand the role of TNF-α in cancer progression and immune responses. Its application extends to developing novel treatments for diseases where TNF-α plays a critical role.